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Abstract 
We report that 10% of melanoma tumors and cell lines harbor mutations in the FGFR2 gene. 
These novel mutations include three truncating mutations and 20 missense mutations occurring 
at evolutionary conserved residues in FGFR2, as well as among all four FGFRs. The mutation 
spectrum is characteristic of those induced by UV radiation. Mapping of these mutations onto 
the known crystal structures of FGFR2, followed by in vitro and in vivo studies show these 
mutations result in receptor loss of function through several distinct mechanisms, including loss 
of ligand binding affinity, impaired receptor dimerization, destabilization of the extracellular 
domains and reduced kinase activity. To our knowledge this is the first demonstration of loss-of-
function mutations in a Class IV receptor tyrosine kinase (RTK) in cancer. Taken into account 
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with our recent discovery of activating FGFR2 mutations in endometrial cancer, we suggest that 
FGFR2 may join the list of genes that play context-dependent opposing roles in cancer. 
  
Introduction  
Melanoma is the most lethal of all skin cancers. The American Cancer Society estimated that 
there would be 59,940 new cases of melanoma and about 8,110 deaths due to melanoma in 
2007. Previous studies in human melanocytes and melanoma cells have revealed that one of 
the hallmarks of melanocytic transformation is a change from paracrine growth factor stimulation 
by the surrounding keratinocytes in the skin to autocrine growth factor stimulation via ectopic 
expression of growth factors and/or receptors by melanoma cells (1, 2). FGF signaling plays a 
prominent role in tissue homeostasis by providing bidirectional paracrine communication 
between mesenchymal and epithelial cells of parenchymal organs including skin. The FGF 
family comprises 18 ligands (FGF1-FGF10 and FGF16-FGF23) which signal through four 
transmembrane receptor tyrosine kinases (FGFR1-FGFR4) and their tissue specific alternatively 
spliced b (epithelial) and c (mesenchymal) isoforms (3). Previous studies have demonstrated 
that survival and proliferation of melanocytes depends on FGF2 which is provided by the 
surrounding keratinocytes in the skin. A number of functional studies have implicated both FGF2 
and FGFR1 signaling in melanoma progression. Adenoviral transduction of melanocytes with 
FGF2 resulted in phenotypic changes consistent with increased tumorigenicity (4, 5) and 
downregulation of FGF2 via antisense oligonucleotides in metastatic melanoma inhibited 
proliferation and colony formation in soft agar (6, 7). Introduction of antisense oligonucleotides 
targeted towards FGFR1 into melanocytes and metastatic melanoma cell lines resulted in 
decreased proliferation and signs of differentiation (8, 9). Furthermore, injection of an antisense 
FGFR1 construct into primary and metastatic melanomas grown in nude mice has also been 
shown to result in inhibition of tumor growth and induction of apoptosis (10, 11).  
Constitutive activation of FGFRs through chromosomal translocation, aberrant splicing, 
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or missense mutations has been reported in several cancers. The Catalog of Somatic Mutations 
in Cancer (COSMIC) provides a repository of all somatic changes reported to date in this 
receptor family (http://www.sanger.ac.uk/genetics/CGP/cosmic/).  To date FGFR3 is mutated at 
highest frequency in benign seborrheic keratoses and bladder cancer and to a lesser extent in 
multiple myeloma, and cervical cancer. We have recently reported the presence of activating 
mutations in FGFR2 in 16% of endometrioid endometrial cancers (12).  
We report here the identification of novel FGFR2 mutations in 15/113 (13%) of 
melanoma cell lines and 8/100 (8%) of uncultured melanoma tumors.  Mapping of these 
mutations onto the known crystal structures of FGFR2 together with in vitro and in vivo 
functional analyses show that these mutations result in receptor loss of function.  
 
Results 
Identification of FGFR2 mutations in melanoma cell lines and uncultured primary and metastatic 
melanoma tumors  
We screened an initial panel of 47 melanoma cell lines for the presence of mutations in the 
FGFR1-4 genes by sequencing. Following the identification of mutations in FGFR2, 66 
additional melanoma cell lines were screened for FGFR2 mutations using a combination of 
dHPLC and sequencing leading to the identification of fifteen different FGFR2 mutations (Table 
1). None of these mutations were observed in a panel of lymphocyte DNA from 150 Caucasian 
controls (data not shown), suggesting that these mutations arose somatically. Of the 15 cell 
lines carrying FGFR2 mutations, 11 also carried mutations in either BRAF or NRAS (Table 1). 
No mutations were identified in either FGFR1 or FGFR3, while one mutation at a non-conserved 
codon was found in FGFR4, P716R.  
Next, we screened a panel of 28 metastatic melanoma tumors and a panel of 72 vertical 
growth phase (VGP) primary melanomas representing samples from different melanoma 
subtypes for the presence of mutations in FGFR2 gene. We identified mutations in 3/28 
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metastatic samples and 5/72 primary tumors respectively (Table 1).  Subset analysis revealed 
FGFR2 mutations in 1/17 (6%) superficial spreading melanomas (SSM), 2/10 (20%) lentigo 
maligna melanomas (LMM), 1/28 (4%) acral melanomas (AM), and 1/17 (6%) mucosal 
melanomas (MM). For three of these tumors, we were able to extract DNA from surrounding 
normal tissue and in all cases the mutation was only present in the tumor, confirming the 
somatic origin of these mutations. Reminiscent of the “mutator phenotype” seen in the breast 
cancer kinome screen (13), one metastatic tumor was found to carry four different FGFR2 
mutations (V77M, E574K, S688F, P708S), which were not further analyzed as there was a high 
probability that these mutations represented ‘passenger’ mutations rather than ‘driver’ 
mutations. Notably, two primary tumors carried nonsense mutations (Table 1). The majority 
(20/22) of FGFR2 mutations occurred at residues that are conserved across FGFR1-4 or at 
residues that are conserved in 3/4 of the FGF receptors as well as conserved in FGFR2 across 
evolution (data not shown). Mutations in both NRAS and BRAF were observed in tumors with 
FGFR2 mutations at similar frequencies to that reported in the literature. 
  
Mapping of FGFR2 mutations within known FGFR2 structures 
Extracellular mutations  
To gain insights into how the different FGFR2 mutations might impact receptor function, we 
analyzed them in the light of our crystallographic data on FGFRs.  The E219K, G227E, V248D, 
R251Q and G271E mutations, which affect residues in the extracellular region of FGFR2, were 
mapped onto the crystal structure of the 2:2:2 FGF2-FGFR1c-heparin dimer (PDB entry 1FQ9) 
(14) (Figure 1).  We intentionally chose this structure instead of the crystal structure of the 1:1 
FGF2-FGFR2c monomer in order to evaluate the impact of the mutations on heparin/heparan 
sulphate (HS) and FGF-induced FGFR dimerization. In the dimer, two centrally located FGFRs 
interact with each other directly and each receptor makes contacts with both ligands as well.   
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Ligand interacts with the second and third immunoglobulin domains (hereafter referred 
to as D2 and D3) and the interconnecting D2-D3 linker. The R251Q mutation maps to the highly 
conserved D2-D3 linker region (Figure 1, panel B).  In the structure, R250, the residue 
homologous to R251 of FGFR2, makes three hydrogen bonds with its primary FGF2 suggesting 
that the R251Q mutation should diminish the binding affinity of FGFR2 towards FGF2 (Figure 1, 
panel B).  By contrast, the E219K mutation maps to the secondary ligand binding site on D2.  In 
the dimer, D218, which corresponds to E219 of FGFR2, makes a hydrogen bond with K35 of 
the secondary FGF2 ligand (Figure1, panel E).  Therefore, based on the structure, E219K 
should not affect the ability of FGFR2c to bind FGF2, but it should reduce the ability of FGFR2 
to undergo FGF and heparin-induced dimerization.  
Other extracellular mutations including V248D, G227E and G271E are predicted to 
destabilize the tertiary fold of either D2 (V248D and G227E) or D3 (G271E).  V247, which 
corresponds to V248 of FGFR2, is situated at the C-terminal end of the βG strand in D2 where 
its side chain is surrounded by other hydrophobic residues inside the hydrophobic core of D2 
(Figure 1, panel A). Substitution of V248 with the charged aspartic acid should be detrimental to 
the tertiary folding of D2.  G226, which corresponds to G227 in FGFR2c, maps to the start of the 
βF strand in D2 and spatially is in close vicinity to V247 (Figure 1, panel A).  G270, which 
corresponds to G271 in FGFR2, maps to the loop between the βA’ and βB strands in D3 (Figure 
1, panel C).  Each glycine residue provides hydrogen bonds that contribute to the proper β 
strand formation in D2 and D3, respectively. Therefore, based on the structure, these 
substitutions should cause local structural perturbations, which could ultimately impact the 
folding of the whole D2 and D3 respectively. Destabilization of D2 and D3 is predicted to impair 
the correct intramolecular disulphide bridge formation in D2 or D3, leading to exposure of the 
conserved cysteines and allowing them to form intermolecular disulfide-bridged receptor dimers. 
Page 6 
This destabilization can also interfere with the correct processing/maturation and trafficking of 
the mutated receptor through the ER/Golgi, resulting in receptor mislocalization.  
Based on the structure, the E160A and H213Y mutations are likely to impact the 
interaction of FGFR2 with HS.  In the structure, E159 of FGFR1, which corresponds to E160 of 
FGFR2, facilitates the conformation of gA helix in D2, on which a key lysine residue involved in 
HS binding resides (Figure 1, panel D).  Therefore, destabilization of the gA helix due to the 
E160A mutation should negatively impact FGFR2-HS interaction and thereby attenuate FGF- 
and HS-mediated FGFR dimerization.  T212, the residue corresponding to H213 of FGFR2, 
points into the heparin binding canyon of the 2:2:2 FGF2-FGFR1-HS dimer (Figure 1, panel D) 
and the bulkier tyrosine side chain at this location could cause steric clashes with HS 
oligosaccharide molecules leading to inefficient receptor dimerization.  
 
Kinase domain mutations  
Over half of the melanoma mutations affect the conserved tyrosine kinase domain of FGFR2, 
and mapping of these mutations onto unphosphorylated and phosphorylated FGFR2 kinase 
domain structures (PDB ID: 2PSQ and 2PVF)(15) suggests that they also represent loss-of-
function mutations (Figure 2).  Notably, M640 and I642 localize onto either end of the βb8 strand 
(Figure 2, panel B), a secondary structure element that precedes the activation loop (A-loop) of 
the kinase domain. The hydrophobic side chains of these residues are in contact with residues 
in the αE helix in the inner most core of the C-lobe of the kinase domain.  Substitutions of either 
residues with the smaller hydrophobic residues isoleucine or valine respectively would cause a 
cavity within the core of the kinase that should induce local structural perturbations that 
ultimately impact the conformation of the activation loop. The A648T mutation maps to the 
activation loop of the kinase domain (Figure 2, panel E) and is also expected to lead to loss of 
function.  This is because in the phosphorylated activated kinase domain of FGFR2 (PDB ID: 
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2PVF)(15), the methyl group of A648 makes hydrophobic contact with M537 in the αC helix 
which contributes to the correct positioning/orientation of the αC helix relative to the C-terminal 
lobe of the kinase, and hence to the productive alignment of the catalytic residues for the 
phosphotransfer reaction (15).  A threonine is unfavorable at this location as its larger side chain 
is predicted to sterically hinder the αC helix from approaching sufficiently close to the C-terminal 
lobe and consequently, the catalytic residues would not be aligned for the phosphotransfer 
reaction.  
The E636K mutation maps to the loop region between the β7 and β8 strands (Figure 2, 
panel A).  In the structure, the side chain of E636 makes a solvent-exposed hydrogen bond with 
S568 which is located in the hinge region of the kinase domain, suggesting that it may play a 
role in regulation of the spatial positioning of the N-terminal and C-terminal lobes of the kinase 
relative to each other.  Based on the structure, the E636K mutation should influence the kinase 
activity of the FGFR2 kinase domain. The E475 is part of the WE consensus motif that defines 
approximately the N-terminal boundary of the conserved kinase domain in many receptor 
tyrosine kinases.  E475 engages in two strong hydrogen bonds with T555, whose methyl group 
is in hydrophobic contact with residues in αC helix (Figure 2, panel D).  Hence, these 
interactions hold the αC helix in an orientation found in unphosphorylated inhibited kinases.  In 
the phosphorylated activated kinase domains, however, these hydrogen bonds are weaker and 
concomitantly the C-helix moves closer towards C-lobe.  Loss of these hydrogen bonds due to 
the E475K mutation could relieve this inhibition and potentially lead to activation of the kinase 
domain. Alternatively, the E475K mutation could introduce structural instability in the N-lobe of 
the kinase and reduce the half life of the mutant FGFR2.  The G701S mutation maps to the loop 
between αF and αG helices (Figure 2, panel F) and facilitates the conformation of this loop 
region, which makes several hydrogen bonds with K668 in the activation loop.  Therefore, the 
structural perturbations induced by G701S mutation could indirectly lead to reduced kinase 
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activity. The R759Q mutation maps to the C-terminal end of αI helix, the last secondary 
structure element of the kinase domain.  In the structure R759 makes hydrogen bonds with two 
other residues in its vicinity (Figure 2, panel C), and loss of these hydrogen bonds due to the 
R759Q mutation could also induce subtle structural changes leading to a loss in kinase activity.  
The L770V mutation should reduce the ability of FGFR2 to activate PLCγ signaling 
pathway.  L770 follows the Y769, the major phosphorylation site of FGFR2 which serves as the 
docking site for SH2 domains of PLCγ and thus is required for PLCγ phosphorylation and 
activation by the activated FGFR2.  NMR solution structure of PLCγ SH2 domain in complex 
with phosphopeptide indicates that SH2 domain of PLCγ interacts with pTyr and residues +1 to 
+6 positions relative to the pTyr  Hence, the L770V mutation should reduce the affinity of SH2 
domains to the activated FGFR2.  The L770V mutation could also reduce Y769 phosphorylation 
because the substrate binding pocket of the kinase domain prefers a leucine over a valine next 
to the tyrosine phosphorylation site (Chen and Mohammadi, unpublished results).  The reduced 
phosphorylation of Y769 could in turn reduce the ability of FGFR2 to activate the PLCγ pathway. 
Table 2 summarizes the different mechanisms of loss of function by the melanoma mutations 
inferred from crystal structures. Consistent with these analyses predicting that the FGFR2 
mutations are loss-of-function mutations, two melanoma samples harbored nonsense mutations 
and a third sample carried a splicing mutation that would result in premature termination of 
FGFR2 protein translation (Table1).   
 
Analysis of FGFR2 melanoma mutations in vitro 
To test our structural predictions for the extracellular mutations on FGFR2 function, we 
expressed recombinant wild type and mutant ectodomains in E. coli, isolated the inclusion 
bodies enriched in the proteins and subjected them to in vitro refolding.  As a positive control we 
also used the S252W mutant ectodomain.  We have previously shown that the S252W mutation 
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has no adverse effect on folding of FGFR ectodomain (16).  We were unable to refold in vitro 
the ectodomain proteins containing the G227E, V248D, and G271E mutations consistent with 
structural predictions that these mutations are detrimental to the tertiary fold of D2 and D3 
domains.  By contrast, the R251Q mutant ectodomain folded in vitro with yields similar to those 
of the wild type and S252W mutant receptor. We then used surface plasmon resonance to 
analyze the effect of the R251Q mutation on ligand binding affinity of FGFR2c.  Consistent with 
structural predictions, the R251Q mutation severely impaired the ability of FGFR2c to bind 
multiple FGF ligands including FGF2 (Figure 3) and FGF1, 4, 7, 8 and 10 (data not shown).  On 
the other hand, as expected, the S252W mutation enhanced the affinity of FGFR2c towards 
FGF2 and other FGFs (16-18) (data not shown). 
To test the impact of kinase domain mutations, we prepared recombinant wild type and 
mutant kinase domain proteins harboring the E475K, D530N, I642V, and A648T melanoma 
mutations and subjected them to in vitro kinase assays.  Consistent with structural predictions, 
the D530N, I642V and A648T mutant kinase domains exhibited reduced kinase activity relative 
to the wild type kinase domain (Figure 4).  Interestingly, the E475K mutant exhibited a slight 
increase in kinase activity relative to the wild-type kinase domain.  Notably, the protein 
expression yield for the E475K mutant kinase was several fold less than that of wild type kinase, 
suggesting this mutation was partially destabilizing the kinase domain.  
 
Analysis of FGFR2 mutations in cultured cells  
We next analyzed the impact of several mutations (G227E, R251Q, G271E, E475K, D530N, 
I642V and A648T) on the receptor trafficking and maturation of the full length FGFR2c.  Three 
different FGFR2 mutants harboring C278F, S252W or K517R served as controls.  The C278F 
activating mutation associated with Crouzon Syndrome was used to assess the impact of 
destabilizing D3 on both receptor maturation and activation.  This mutation has been shown to 
result in impaired receptor processing, constitutive dimerization and increased signaling from 
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intracellular compartments (19). In contrast, the S252W mutation observed in patients with 
Apert syndrome has no impact on receptor folding (18). The K517R mutant receptor served as a 
kinase deficient receptor.  K517 coordinates the phosphate groups of ATP and its mutation to 
arginine in the homologous FGFR3 has been previously shown to abolish kinase activity (20).   
Following transfection of wildtype FGFR2 receptor into HEK293 cells, two major FGFR2-
immunoreactive bands (110kDa and 130kDa) are observed.  PNGase digestion resulted in the 
reduction in size of both bands to a single 98KDa band (open arrow) confirming these two 
bands are differently glycosylated receptor populations (Figure 5a). EndoHf digestion, which is 
known to remove N-linked high mannose moieties but not complex carbohydrates from 
glycosylated proteins, resulted in the reduction of the 110kDa band to 98kDa but had no effect 
on the mobility of 130kDa band.  These data show that the 110kDa form represents immature 
partially processed receptor present in the ER and early Golgi, whereas the EndoHf resistant 
130kDa band represents the fully glycosylated mature receptor. Densitometric analysis 
indicates that the EndoHf resistant 130kDa mature form comprises ~60% of the wildtype FGFR2 
(Figure 5a, 5b).  The R251Q and S252W mutations did not reduce the relative proportion of 
EndoH resistant 130kDa mature form, which is fully consistent with our structural predictions of 
no adverse effects on protein stability by these mutations.  In contrast, only 30% of G227E, 
V248D, G271E and C278F mutants were EndoHf resistant, suggesting impaired receptor 
processing of these FGFR2 mutants.  This is also consistent with our structural predictions that 
these mutations will adversely impact structural integrity of D2 or D3 domain of FGFR2 (Figure 
5b upper panel). There was a small increase in the relative proportion of the 110kDa band for 
the E475K mutant (Figure 5b, lower panel), consistent with the decreased protein yield 
observed in the in-vitro kinase assays.  
 To confirm altered cellular localization of the mutants, we performed 
immunofluorescence (IF) studies in transiently transfected HEK293 cells. In cells transfected 
with wildtype FGFR2, positive immunofluorescence signal was distributed primarily in the 
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plasma membrane and also in the rough ER and Golgi (Figure 5c). In cells transfected with the 
G227E mutant (Figure 5c) however, there was positive perinuclear staining, particularly evident 
around the nuclear membrane as well as a dispersed reticular staining indicative of retention in 
the ER.  IF also demonstrated mislocalization to intracellular membrane and decreased cell 
surface expression for FGFR2 mutants V248D, G271E and C278F. In contrast, IF of the A648T 
mutant shows clear cell surface localization in keeping with the structural predictions and 
EndoHf analyses. To confirm the ER localization of the G227E mutant, we then performed 
similar IF studies looking for colocalization with the ER resident protein, protein disulphide 
isomerase (PDI) which revealed a high degree of colocalization of the two proteins confirming 
impaired receptor localization (Figure 5d). In contrast, marked cell surface localization and 
limited colocalization with PDI was observed for both the wildtype FGFR2 and the E219K 
mutation, predicted to have no detrimental effect on receptor folding.  
 
BaF3 proliferation assay and p44/42 MAPK phosphorylation in response to FGF2 as readout of 
receptor function 
We next analyzed the effects of the melanoma mutations on FGFR2c activity. Given that 
melanocytes and melanoma cell lines express other FGFRs whose activation may mask the 
ability to specifically evaluate FGFR2 signaling and function, we used the murine interleukin-3 
dependent pro-B BaF3 cell line to determine receptor activity. The BaF3 cell line is routinely 
used as a model system for the evaluation of FGFR function, as it does not express 
endogenous FGF ligands or receptors. Although BaF3 cell proliferation and survival is normally 
dependent on IL-3, activated tyrosine kinase signaling can substitute for IL-3 to maintain cell 
viability and proliferation. We included the N549K FGFR2 receptor as a constitutively activated 
positive control as this activating mutation has been reported in endometrial cancer (12) and an 
identical mutation at the paralogous positions in FGFR3 has been associated with 
hypochondroplasia (N540K) (21). Polyclonal stable lines were generated following lentiviral 
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transduction and selection in Geneticin. Proliferation assays were then performed in the 
absence of IL3 and the presence of 1nM FGF-2 and 10ug/mL heparin and cell viability assayed 
after five days. As anticipated, the constitutively active N549K mutant resulted in levels of 
proliferation above that achieved by the wildtype receptor, whereas expression of all mutant 
constructs including G227E, G271E, E475K, I642V and A648T FGFR2 resulted in reduced cell 
proliferation compared to wildtype FGFR2 (Figure 6a), verifying that these mutations impaired or 
abrogated the ability of FGFR2 to stimulate cell proliferation in response to ligand in an in vivo 
setting. Surprisingly, the N549K mutation did not cause constitutive BaF3 proliferation in the 
absence of ligand stimulation.  
As a further assessment of receptor impairment due to mutation, we examined the ability 
of the receptor to activate the pro-proliferative p44/42 MAPK signaling pathway in response to 
exogenous rFGF2. With the exception of the N549K known activating mutant, all mutations 
resulted in a reduction to varying levels in the ability of the receptor to induce phosphorylation of 
p44/42 MAPK. (Figure 6 b, c & d) 
 
Reintroduction of FGFR2 into melanoma cells 
We next sought to determine whether reintroduction of FGFR2 could suppress proliferation of 
melanoma cells. RTPCR with isoform specific primers and subsequent sequencing revealed 
normal human melanocytes and the majority of melanoma cell lines expressed the 
mesenchymal FGFR2c isoform (data not shown). For this reason our reintroduction studies 
utilized the FGFR2c isoform. We overexpressed FGFR2c in melanoma cell lines that lacked 
FGFR2 expression by RT-PCR (SbCl2), and in melanoma cell lines that expressed mutant 
FGFR2 (AO4, D22, UACC2534) and assessed proliferation.  Surprisingly, reintroduction of 
FGFR2 failed to suppress proliferation of these melanoma cell lines (Figure 7a).  Expression of 
FGFR2 following lentiviral transduction was confirmed by Western blot analysis for each cell line 
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(Figure 7b). Similar results were also achieved in both the D22 and UACC2534 melanoma cell 
lines (data not shown). 
  
Discussion  
In this study we report novel FGFR2 mutations in 15/116 melanoma cell lines and 8/100 
uncultured metastases and primary tumors. In order to determine the ratio of non-synonymous 
to synonymous mutations in our dataset, we went back and examined the synonymous variants 
we identified. As we did not have constitutional DNA for these samples, we excluded them as 
probable somatic mutations if they had been previously identified in dbSNP. Several additional 
synonymous variants occurred alongside each other in multiple individuals, consistent with the 
presence of a rare germline haplotype block. Following the exclusion of these putative SNPs, 4 
synonymous variants remained, therefore the conservative ratio of non-synonymous to 
synonymous mutations in our dataset was 23:4, which exceeds the 2:1 ratio one would expect if 
these were random passenger mutations and supporting a role for these mutations in 
melanoma pathogenesis. Furthermore, the mutations spectrum is characteristic of those 
induced by UV radiation, namely 70% of the mutations were C:G>T:A substitutions with one 
CC:GG>TT:AA tandem mutation.  The presence of characteristic UV mutations in FGFR2 
suggest that mutation of this gene is possibly an early event in transformation, and we anticipate 
that further sequencing analysis in a greater number of primary tumors and nevi will shed light 
on when during melanoma development these mutations arise. It should be noted that the 
mutation frequency reported in this study may be an underestimate. This is based on the fact 
that 40 cell lines were screened by dHPLC rather than sequencing, exons 2-5 were not 
screened in this latter panel of cell lines, and not all primary tumors provided high quality 
sequence for all exons.   
Insights gained from mapping these mutations onto known FGFR2 crystal structure, 
combined with in vitro and in vivo functional studies show that these mutations lead to loss of 
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receptor activity through different mechanisms, including loss of ligand binding (R251Q); 
incomplete processing of the receptor and retention in the ER (V248D, G227E, G271E); and 
complete or partial loss of tyrosine kinase activity (A648T, D530N, I642V). Future studies 
confirming the structural predictions described herein may also reveal that FGFR2 loss-of-
function can occur through impaired FGF and HS induced receptor dimerization and reduced 
binding to PLCγ.  
The loss of function nature of our identified melanoma mutations is also consistent with 
published literature.  In support of D530N resulting in FGFR2 loss-of-function, a germline 
D771N mutation at the equivalent codon in RET has been associated with Hirschsprung’s 
disease, commonly due to loss-of-function mutations in RET (22). Also, while these studies 
were underway, the A648T FGFR2 mutation was identified in the germline of affected patients 
in two independent families with autosomal dominant lacrimo-ariculo-dento-digital (LADD) 
syndrome (OMIM 149730) (23).  Consistent with our in vitro and in vivo data a recent study 
showed that the A648T mutation abrogated tyrosine kinase activity of FGFR2 (24).  As 
discussed earlier, we propose that this mutation creates a steric barrier for the movement of the 
kinase N-lobe towards the C-lobe which is predicted to take place when the kinase transits from 
the basal “low” activity state to the “active” state.  However, precise definition of the mechanism 
by which A648T mutation impairs FGFR2 kinase activity awaits the resolution of crystal 
structure of the mutant kinase domain as was recently carried out for an A628T LADD mutation.  
In contrast to the A648T mutation, the A628T mutation maps onto the catalytic loop of the 
kinase domain and the crystal structure of the mutant kinase shows that this mutation acts by 
introducing steric conflicts that alter the productive arrangement of the neighboring key catalytic 
residues (25). 
A comparison of the mutations identified in melanoma to those our lab previously 
identified in endometrial cancer highlights the differences in the mutation spectra (Figure 8). The 
majority of the endometrial mutations (17/20) are identical to FGFR2 and FGFR3 mutations 
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previously reported in the germline, a finding similar to that observed for FGFR3 where a 
comparison of FGFR3 mutations reported in cancer with germline mutations associated with 
skeletal disorders shows a remarkable concordance, reviewed in (26, 27). In contrast, the more 
than 20 FGFR2 mutations we identified in melanoma were all novel, supporting our findings that 
the mutations are distinct and different from the many gain-of-function mutations previously 
identified in the FGFRs.  
This discovery of loss of function mutations in an RTK is unexpected, given the 
conventional wisdom that activation of receptor tyrosine kinases (eg KIT, FLT3 and FGFR3) 
drive tumorigenesis and our previous report documenting the presence of activating mutations 
in FGFR2 in endometrial cancer (12). However, it should not be surprising given that a variety of 
RTK signaling pathways can induce either proliferation or differentiation depending on the cell 
type.  Indeed, Cre-Lox transgenic mice where FGFR2b has been deleted in cells expressing 
keratin V develop spontaneous papillomas. Moreover, following DMBA and TPA treatment, 
these transgenic mice developed an increased number of papillomas and carcinomas compared 
to widltype mice, providing support that FGFR2 can act as a tumor suppressor gene in some 
cell types (28).  Furthermore, loss of FGFR2 expression has been associated with several 
cancers including prostate and bladder (29-31). Reintroduction of FGFR2 resulted in decreased 
growth in vitro and reduced tumorigenicity in vivo of bladder carcinoma cells (32), prostate 
tumor cells (33-35) and salivary adenocarcinoma cells (36).  
Based on these data and our structural, biochemical and biological data supporting the 
characterization of the FGFR2 mutations identified in melanoma as loss of function, it was 
indeed surprising that reintroduction of FGFR2 failed to suppress proliferation of melanoma cell 
lines. There are several possible explanations for these apparent disparate results. One 
difference between the previously published reintroduction results and the current melanoma 
study is that they involve different FGFR2 spliceforms. The previous studies were all carried out 
in cells of epithelial origin with the FGFR2 IIIb isoform whereas our studies evaluated 
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proliferation following reintroduction of FGFR2 IIIc, the isoform of FGFR2 expressed in 
mesenchymal cells and in the melanocytes, which are derived from the neural crest. The lack of 
suppression of proliferation of melanoma cells following overexpression of FGFR2 may 
therefore reflect a cell lineage specific function of FGFR2. Another possible explanation is that 
loss or abrogation of FGFR2 is an early event and those melanoma cell lines have acquired 
additional genetic aberrations that prevent suppression of proliferation following FGFR2 
reintroduction. Alternatively, abrogation of FGFR2 may not contribute to melanoma 
pathogenesis by removing a growth inhibitory signal. Indeed, though tumor suppressors 
classically function to regulate cell cycle, accumulating evidence suggests that additional 
subsets of genes exist which function to suppress tumorigenesis not by inhibiting proliferation, 
but by altering other aspects of the malignant phenotype, including loss of contact inhibition, 
angiogenesis, cell migration, and metastasis.  Therefore, the pathogenic consequence of loss of 
FGFR2 function may not directly involve cell cycle regulation, but instead impact another aspect 
of tumorigenesis. The caveat exists that loss of FGFR2 might not be a driver of cell 
transformation but rather these mutations occur as a consequence of the oncogenic state, 
however their selection in 10% of melanoma samples would argue that they must provide a 
selective advantage to the cells in which they arose. This is consistent with a relatively high 
frequency and high non-synonymous to synonymous ratio arguing against their presence as 
passenger mutations.  
Elucidation of the mechanism by which FGFR2 contributes to melanoma is also 
complicated by our current lack of understanding as to the differing cellular functions of the 
multiple splice forms of these receptors, particularly in the melanocytic system. There are 
additional splice variants affecting the ligand binding domain (2 Ig, 3 Ig), cytoplasmic 
juxtamembrane domain (+VT, -VT), and C-terminal domain of FGFR2 (C1, C3), and the role of 
these splice variants in normal melanocyte function and melanoma pathogenesis is currently 
unknown. Our lab is currently investigating the relative expression levels of these various 
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isoforms and their functional significance in melanocytes and melanoma. FGFR2 may also have 
cellular functions distinct from typical RTK signaling. There have been reports that FGFR1 binds 
CBP and RSK in the nucleus (37) and we and others have observed FGFR2 localized to the 
nucleus in various cell types (unpublished results) (38). Lastly we and others have shown that 
FGFR2 can heterodimerize with FGFR1 at least in vitro (unpublished results) (39) and FGFRs 
have also been shown to bind to other molecules at the cell surface including NCAM (40). We 
postulate that a more complete understanding of FGFR biology will allow us to identify the 
mechanism by which loss of FGFR2 contributes to melanoma initiation and/or progression.  
In conclusion, we provide strong genetic, biochemical, in vitro and in vivo evidence that 
loss of function FGFR2 mutations occur in a subset of melanomas. Though we have yet to 
uncover the biological consequence of loss of FGFR2 function in melanoma, we propose that 
FGFR2 should join the list of those genes that play context dependent opposing roles in 
tumorigenesis. Although many genes have been shown to have context dependent opposing 
roles in cancer eg Notch, TGFβ (41), FGFR2 may be the first gene in which both loss and gain 
of function mutations have been reported in different tissue types. Ongoing work in our 
laboratory is targeted towards understanding the molecular mechanisms by which loss of 
FGFR2 contributes to melanoma pathogenesis.  
 
Experimental Procedures 
See Supplemental Methods for details regarding mutation detection.  
 
Expression, refolding and purification of ectodomain of FGFR2 
DNA fragment encoding residues 147 to 366 of FGFR2c was amplified by PCR and subcloned 
into pET-28a bacterial expression vector using NcoI and HindIII cloning sites.  Point mutations 
(G227E, V248D, R251Q, S252W and G271E) were introduced using QuikChange site-directed 
mutagenesis kit (Stratagene). BL21(DE3) competent cells were transformed with wild type or 
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mutant expression constructs and protein expression was induced with 1mM IPTG for 5 hours 
at 37°C.  Cells were lysed using French press, centrifuged, and the inclusion bodies containing 
wild type or mutant proteins were dissolved in 6 M guanidinium hydrochloride plus 10 mM DTT 
in 100 mM Tris-HCl buffer (pH 8.0). The solubilized FGFR2 proteins were subjected to an in 
vitro refolding by slow dialysis against 25 mM HEPES buffer (pH 7.5) containing 150 mM NaCl, 
10% Glycerol, and L-Cysteine.  The correctly refolded wild type and mutant proteins were then 
sequentially purified by heparin affinity and size exclusion chromatography. SPR analysis was 
performed as described previously (18).  
 
Expression and purification of FGFR2 kinase domain 
The DNA fragment encoding residues 458 to 768 of human FGFR2 was subcloned into pET 
bacterial expression vectors with an N-terminal 6XHis-tag to aid in protein purification. Point 
mutations (E475K, D530N, I642V, and A648T) were introduced using QuikChange site-directed 
mutagenesis kit (Stratagene).  The bacterial strain BL21(DE3) cells were transformed with wild 
type or mutant FGFR2 kinase expression constructs and protein expression was induced with 1 
mM IPTG for 4 hours at ambient temperature.  The cells were then lysed using a French press, 
and the soluble kinase proteins were purified by using sequential Ni2+-chelating, anion exchange 
and size exclusion chromatography. The purity of the proteins was estimated to be over 98% 
based on SDS-PAGE analysis.  Purified wild type and mutant kinase proteins were 
concentrated to at least 10 mg/ml using a Centricon-10.   The autophosphorylation activity of the 
wild type and mutant kinases was compared using a continuous spectrophotometric kinase 
assay according to the published protocol (42). 
 
Site-directed mutagenesis of full length FGFR2 
 All mutations were introduced to the pcDNA3_FGFR2 wildtype plasmid (NM_000141) using the 
Quikchange II XL Site Directed Mutagenesis Kit (Stratagene) according to manufacturers 
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instructions. Additionally, mutagenesis primers were designed to introduce a novel, but silent 
(non-coding change) restriction enzyme (RE) recognition site to allow for fast, preliminary 
screening of clones. The full list of primer sequences can be found in Supplementary Table 1 
online. After RE screening, the entire coding sequence of FGFR2 was sequenced for each 
clone to confirm the presence of the intended mutation and to ensure that no other mutations 
were introduced during the mutagenesis process. Plasmid DNA was then isolated using Qiagen 
EndoFree Plasmid DNA Isolation kits and DNA with A260/280 >1.8 was used in all subsequent 
experiments. 
 
Cell lines and transfections 
 All cell lines described in this series of experiments were maintained under standard culturing 
conditions as described by the ATCC or DSMZ (Germany; BaF3 cell line). Transient 
transfections of 1ug total DNA (constisting of 250 ug wildtype or mutant FGFR2 + 750 ug empty 
plasmid) were achieved with FuGene 6 (Roche) at a 3:1 ratio of reagent:DNA according to 
manufacturers instructions. 
 
Cell Lysis, Endoglycosidase digestions and Western blotting 
Thirty six to 48 hours post transfection, cells were washed with ice-cold PBS and lysed in ice-
cold lysis buffer (20 mM Hepes pH 7.4, 1% Triton X100, 2 mM EGTA, 10% glycerol, Complete 
Protease Inhibitor Cocktail (Roche), 1 mM NaF, 1 mM Na3VO4, 100 uM PMSF). For PNGase 
and EndoHf digestions, 20 ug of lysate was subjected to digestion according to manufacturers 
recommendations. Protein was resolved on 3-8% Tris acetate gels and transferred to PVDF 
membranes (Invitrogen). After blocking the membranes with 5% skim milk/TBST, membranes 
were probed with 1:2000 Bek C-17 (Santa Cruz Biotechnology). 
 
Immunofluorescence 
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 Cells were transfected as described and plated onto 8-well chamber slides. After 36-48 hours 
they were fixed with 4% paraformaldehyde, permeabilized in 0.2% Triton and incubated with 
1:300 Bek C-17 and 1:1000 anti-PDI (Invitrogen) and detected with goat ant-rabbit Cy3 (1:200; 
Jackson ImmunoResearch) and goat anti-mouse AlexaFluor 488 (1:1000; Invitrogen) 
respectively. Slides were mounted with Pro Long Gold antifade reagent and imaged on a Zeiss 
LSM 5 Pascal confocal microscope. 
 
Lentivirus production 
293FT cells on poly-D-lysine coated plates were transfected with lentiviral packaging vectors 
and pTYF.FGFR2.IRES.Neo (or mutant FGFR2) using Superfect (Qiagen) at a 4:1 
Superfect:DNA ratio as per manufacturers instructions. Media containing the virus was collected 
at 24 and 40 hours, pooled, filtered through a 0.45 um low protein binding filter and stored at -
80oC until use. Viral stocks were tittered in HEK293 cells following serial dilution in a six well 
plate, selection for fourteen days in 800ug/ml Geneticin, staining with crystal violet and colony 
counting.  
 
BaF3 Proliferation assays 
5 x 105 BaF3 cells were infected with an MOI of 1 (5 x 105 viral transducing units (TU)) for 23 
hours, then placed under selective pressure (1200 ug/mL Geneticin) for 14 days in the presence 
of 5 ng/ml IL3. Transduced stably selected BaF3 cells containing wildtype and mutant FGFR2 
were maintained under selection in RPMI/10% FBS containing 50 nM beta-
mercaptoethanol,100U/mLpenicillin/100ug/mL streptomycin sulfate, 1000 ug/mL Geneticin and 
supplemented with 5 ng/mL murine IL-3 (R & D Sytems). Prior to the proliferation assay, cells 
were counted and washed in the above media containing no IL-3. Cells were plated at 1 x 
104/well in triplicate in a 96 well plate, in media containing 16.7 ng/mL (1 nM) FGF-2 and 10 
ug/mL heparin. Half the volume of media was removed at day 3 and replaced with an equal 
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volume containing fresh ligand at 2X concentration and no IL-3. Proliferation was assessed 
using the ViaLight Plus Cell Proliferation/Cytotoxity Kit (Lonza Rockland, Inc.) according to the 
manufacturer’s instructions.  
 
Melanoma proliferation assays   
SbCl2 melanoma cells were cultured in 2% Tumor Medium containing a 4:1 mixture of MCDB 
153 medium with 1.5 g/L sodium bicarbonate and Leibovitz's L-15 medium with 2 mM L-
glutamine supplemented with 0.005 mg/ml bovine insulin, 1.68 mM CaCl2, and 2% fetal bovine 
serum. AO4, D22, and UACC2534 cells were grown in RPMI supplemented with 10% FBS. 
SbCl2, AO4, D22, and UACC2534 melanoma cells were transduced with empty vector, FGFR2, 
or kinase dead FGFR2 (K517R) at an MOI of 2 in the presence of 6 ug/ml polybrene.  Cells 
were selected for at least 14 days in 500-800 ug/ml G418.  2,000-4,000 cells were plated per 
well in a 96 well plate in full growth media. The next day, cells were washed in PBS and 
switched to low serum media overnight (0.5% FBS for SbCl2 and 1% for AO4, D22, and 
UACC2534).  Cells were then stimulated with 10ng/ml FGF2 and 10 ug/ml heparin in low serum 
media and proliferation assessed using the sulforhodamine B (SRB) assay.  Fresh FGF2 and 
heparin were added on day 4.   
 
p44/42 Phosphorylation 
To examine p44/42 MAPK phosphorylation, cells were washed in PBS and resuspended in BaF 
media containing no FBS and no IL-3 (BaF starve media) for 2 hours. Cells were pelleted and 
resuspended in either BaF starve media with 10ug/mL heparin only (unstimulated or “-“) or BaF 
starve media with heparin and 1nM rFGF2 (stimulated or “+”) for 10 minutes at 37oC. After 10 
minutes, the cells were pelleted by brief centrifugation and immediately lysed in ice cold lysis 
buffer. Twenty micrograms total protein was resolved on a 4-12% Bis Tris gel and probed for 
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phosho p44/42 MAPK. Blots were then stripped and reprobed for total p44/42 MAPK (Cell 
Signaling Technologies). 
 Phosphorylation was quantitated using Image J (http://rsb.info.nih.gov/ij/) and presented 
as the ratio of phosporylated over total p44/42 MAPK for each mutant divided by the same ratio 
for the FGF2 stimulated wild type receptor. 
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Figure legends: 
 
Figure. 1. Mapping of FGFR2c extracellular mutations identified in melanoma tumors/cell 
lines onto the known FGF-FGFR crystal structures suggests that these mutations should 
impair FGFR2c activity. The locations of mutated residues in the extracellular region of FGFR2 
are mapped onto the ribbon diagram of 2:2:2 FGF2–FGFR1c–heparin complex (PDB ID: 1FQ9) 
(Schlessinger et al., 2000).  FGF is colored orange and the extracellular ligand binding region of 
FGFR is colored as follows: D2 in green, D3 in cyan, D2–D3 linker in grey.  The two heparin 
oligosaccharides in the dimer are rendered in sticks.  To assist the viewer, certain β strands of 
D2 and D3 domains are labeled. Panels A through E, depict close-up view of the region where 
the mutated receptor residues are located. In each panel, in addition to the mutated residue, 
other relevant receptor residues are shown as ball-and-sticks.  In panel A, the molecular 
interactions of G226 and V247, which correspond to the mutated G228 and V248 in FGFR2, are 
shown.  G226 in βF strand makes hydrogen bonds with L245 in bG strand and contributes to 
proper βF-βG strand pair formation, and hence to overall stability of D2.  V247 engages in 
hydrophobic contacts with other residues in the interior core of D2 and thus plays a critical role 
in folding of D2 as well.  To emphasize these hydrophobic contacts, the surface of V247 and 
neighboring residues are shown in cyan (V247) and purple meshes, respectively.  In panel B, 
R250, homologous to R251 in FGFR2, makes three hydrogen bonds with FGF ligand.  Mutation 
of R251 to Q should substantially reduce binding affinity of mutated FGFR2 towards FGF ligand.  
In panel C, the molecular environments of G270 and N304 in FGFR1, which correspond to the 
mutated G271 and G305 in FGFR2, are shown.  G270 plays a role in formation of turn between 
βA’ and βB by making hydrogen bonds with other residues in D3.  Therefore, mutation of G271 
in FGFR2 should negatively impact the tertiary folding of D3.  N304, on the other hand maps to 
the large loop region between strand βC and βC’ which protrudes from D3 and does not play 
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any apparent role in structural integrity of D3. In panel C, the surfaces of the conserved 
cysteines (C277 and C341) in the interior core of D3 are shown as grey mesh.  In panel D, the 
proximity of E159 and T212 to the heparin oligosaccharide chains in the dimer is emphasized.  
E159 and T212 correspond to E160 and H213 in FGFR2 respectively and mutation of these 
residues in melanoma could alter interaction of mutated FGFR2s with heparin/heparan sulfate.  
Panel E highlights the important role D28 plays in binding of second FGF in the 2:2 FGF–FGFR 
dimer and hence dimerization.  Mutation of E219 in FGFR2, which corresponds to D218 in 
FGFR1, should negatively impact the ability of receptor to undergo ligand- and HS-induced 
dimerization. Atom coloring is as follows: nitrogen in blue, oxygen in red, and sulfur in yellow. 
Hydrogen bonds are shown as dashed lines. Letters N and C denote the N- and C-termini of 
FGFR1c, respectively.  
 
Figure. 2. FGFR2c kinase domain mutations identified in melanoma tumors/cell lines 
mapped onto the crystal structures of the FGFR2 kinase domain suggests that these 
mutations should impair the kinase activity of FGFR2. The positions of the mutated residues 
are mapped onto the crystal structure of unphosphorylated wild type FGFR2 kinase domain 
(PDB entry: 2PSQ) (15).  The coloring of the intracellular tyrosine kinase domain is as follows: 
the N-terminal lobe of kinase in light blue, the C-terminal lobe in bright blue, the activation loop 
is in magenta, the kinase hinge region is in green and the N-terminal tail of the kinase is colored 
wheat. Note that ATP (not shown) binds in the cleft between the N-lobe and C-lobe of the 
kinase domain.  To assist the viewer, certain β strands and α helices, that are relevant for 
explanation of the effects of the melanoma mutations, are labeled.  Panel A shows that E636, 
which maps to the sharp turn between β7 and β8 strands, makes hydrogen bond with S563 in 
the kinase hinge region.  Mutation of this residue to lysine could influence the relative 
disposition of N-lobe to C-lobe, and hence alter the tyrosine kinase activity of FGFR2.  Panel B 
shows that the M640 and I642 side chains (red mesh) point into inner hydrophobic core of 
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kinase domain, and engage C606 and M614 (cyan mesh).  Mutation of either M640 or I642 to 
smaller hydrophobic residues should weaken the extent of these core hydrophobic contacts and 
lead to reduction in kinase activity.  In panel C, the hydrogen bonds between R759 and side 
chains of negatively charged E731 (in helix αH) and D756 (in helix αI) are shown.  In addition to 
the loss of these hydrogen bonds, introduction of stop codon at this location will also truncate 
the helix αI by one helical turn.  These structural changes should reduce the stability of kinase 
domain specifically making kinase domain temperature-sensitive, and ultimately lead to receptor 
loss-of-function.  Panel D shows a close up view of the region where E475 is located.  The side 
chain of E475 engages in two strong hydrogen bonds with side chain and backbone atom of 
T555 (located in the loop between β4 and β5 strand), which facilitate the conformation of the β4-
β5 loop as well of the region preceding E475 itself.  This in turn promotes the hydrophobic 
contacts between L468, T555 (the methyl group) and L560 from these regions and L528, V532 
and M535 in the catalytically important αC helix.  To emphasize this point, the side chains of 
these hydrophobic residues are shown as colored mesh.  Panel E shows the close up view of 
the region where D530 and A648 are located.  In unphosphorylated wild type FGFR2K 
structure, D530 does not play any role.  However, in the A-loop phosphorylated activated 
FGFR2K structure (PDB entry: 2PVF)(15) the side chain of D530 engages in salt bridge with 
R664 in the A-loop and contributes to A-loop conformation in the ‘Active’ state (not shown).  The 
side chain of A648, located at the beginning of A-loop, packs against the hydrophobic side 
chains of M537 in αC helix.  Replacement of A648 with threonine is expected to lead to loss-of-
function since the larger side chain of threonine will impede αC helix from nearing sufficiently 
close enough to the A-loop in the “Active” FGFR2K.  Panel F shows close up view of the kinase 
region where G701 is located.  G701 plays a role in stabilizing the conformation of the loop 
between the helices αF and αG, which is in hydrogen bonding contacts with K668 in the A-loop.  
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The G701S mutation should destabilize the αF-αG loop and indirectly affect the A-loop 
conformation. 
 
 
Figure 3.  SPR analysis shows that the R251Q mutation abrogates ligand binding. (a-b) 
Increasing concentrations of WT (a) or R251Q FGFR2c mutant ectodomain (b) were injected 
over a CM5 chip onto which full length human FGF2 was immobilized. The biosensor chip 
response is plotted as a function of time. SPR analysis performed as previously described (18). 
 
Figure 4. FGFR2 kinase domains harboring melanoma mutations have reduced tyrosine 
autophosphorylation activity. Wild-type FGFR2K and four mutant FGFR2Ks each harboring 
E475K, D530N, I642V, or A648T single mutation, are subjected to in vitro kinase assays. Data 
represent the average of three independent experiments plus standard deviations.  The tyrosine 
autophosphorylation activity of these wild-type and mutant FGFR2Ks were determined using a 
continuous spectrophotometric assay as previously described (42).  
 
Figure 5. Mutations in FGFR2 impair receptor processing and localization (a) Confirmation 
of post translational glycosylation of wild type FGFR2 by PNGase digestion of both the 130kDa 
band (solid arrow)and 110 kDa band (stippled arrow) to a single 98 kDa band (open arrow) in 
HEK293 cells. Sensitivity to digestion with EndoHf of only the 110 kDa band indicates this 110 
kDa band to be immature, partially processed receptor predominantly present in the ER and early 
Golgi. (b) EndoHf digestion of FGFR2 in HEK293 lysates transiently transfected with wildtype 
FGFR2 or mutant FGFR2. Densitometry analysis revealed that the EndoH resistant 130 kDa 
band comprises ~60% of the wildtype FGFR2 but only 30% of G227E, V248D, G271E, and 
C278F mutants. (c) Localization of wildtype and mutated FGFR2 following transient transfection 
into HEK293 cells and immunofluorescent staining. Impaired receptor trafficking is evident for 
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G227E, V248D, G271E and C278F compared to trafficking of the wildtype receptor to the cell 
surface. (d) Immunofluorescent analysis of the colocalization of FGFR2 (red, left panels) and the 
ER resident marker PDI (green, middle panels) confirms the overall retention of the G227E 
mutant receptor in the ER compartment in HEK293 cells (yellow, right panel) when compared 
with the cell surface localization of wildtype FGFR2 and E219K (mapping onto the known 
extracellular crystal structure predicted the latter mutation to have no effect on misfolding).   
 
Figure 6. Cell proliferation in response to FGF2 in BaF3 cell lines stably transduced with 
wildtype and mutant FGFR2_IRES_Neo expression constructs. 
(a) All novel mutations identified in melanoma result in a decrease in BaF3 proliferation when 
compared to wild type FGFR2. Gray bars indicate basal proliferation in the absence of ligand and 
black bars represent proliferation in response to 1nM FGF2. Data represents the average of at 
least two independent experiments assayed in triplicate. (b) Analysis of phospho p44/42 MAPK 
upon stimulation with exogenous rFGF-2 shows that with the exception of the N549K positive 
control, mutations impair the ability of the receptor to activate this pro-proliferation pathway 
compared to wild type receptor. (c) Western blot showing equal expression of FGFR2 by all 
mutants except empty vector in the absence (-) and presence (+) of FGF2. (d) Graphical 
representation of p44/42 MAPK phosphorylation expressed as a percentage of phosphorylation 
(upon ligand stimulation) of that of wild type receptor. 
 
Figure 7.  Reintroduction of FGFR2 failed to suppress proliferation of SbCl2 or AO4 
melanoma cells. 
(a) Melanoma cell lines SbCl2 and  AO4 were stably transduced with empty vector, FGFR2, or 
FGFR2 K517R lentivirus and proliferation was assessed using the sulforhodamine B (SRB) 
assay. Overexpression of FGFR2 or kinase dead FGFR2 K517R had no effect on the 
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proliferation of these melanoma cell lines. (b) FGFR2 expression was confirmed by Western 
blot analysis.  
 
 
 
Figure 8. Schematic representation of FGFR2 mutations highlighting the difference 
spectrum of somatic mutations in melanoma compared to endometrial cancer and also 
germline mutations in craniosynostosis syndromes.  
(a) Novel somatic mutations in FGFR2 identified in melanoma cell lines and uncultured tumors 
are presented in red above the schematic representation of the protein and numbered relative to 
FGFR2c (NP_000132.1). (b) Somatic mutations in FGFR2 identified in primary endometrial 
cancers and cell lines are presented in green (upper panel) above the schematic representation 
of the protein and are numbered relative to FGFR2b (NP_075259.2) (12).  Germline mutations 
associated with a variety of craniosynostosis syndromes and numbered relative to FGFR2c 
(NP_000132.1) are presented in the lower panel (http://www.hgmd.cf.ac.uk/ac/index.php). Novel 
mutations are underlined.  Four somatic FGFR2 endometrial mutations, while not previously 
reported in the germline, have an identical missense change reported in the paralogous position 
in FGFR3c in a skeletal chondrodysplasia (indicated with **) 
(http://www.hgmd.cf.ac.uk/ac/index.php). Note that the majority of somatic mutations in 
endometrial cancer parallel those identified in the germline while every melanoma mutation was 
novel.  
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Table 1. Summary of melanoma samples carrying FGFR2 mutations  
Samples Nucleotide change 
Codon 
change BRAF NRAS 
     
Cell Lines     
MM540 G812A G271E V600E wt 
UACC1940 G913A G305R wt wt 
WSB C1109G T370Rb V600E wt 
M92-001 a G1423A E475Kb wt G13R 
ME10538a G1423A E475K V600E wt 
M91-054 T2308G L770V V600E wt 
UACC2534 G752A R251Q wt wt 
A375 G1906A E636Kb V600E wt 
UACC3093 GG2100-1AA G701S wt Q61L 
D11 G1920A M640I wt Q61L 
MM369 G655A E219K V600E wt 
D22  
D22 
G1588A        
C2275T 
D530N       
R759X 
wt 
wt 
wt 
wt 
MM229 G2276A R759Q L597S wt 
A04 G1942A A648Tb wt wt 
A05 A479C E160A V600E wt 
Metastatic Tumors     
Met19 G680A G227E wt nd 
Met27 C71T S24F nd nd 
Met15 
 
 
G229A        
G1720A       
C2063T      
C2122T 
 
V77M        
E574K        
S688F        
P708S 
 
V600E 
 
nd 
Primary Tumors     
81c IVS15-2A>T g FS V600E wt 
AM169 d T743A V248D wt wt 
AM146 e C637T H213Y wt Q61L 
53 f G1422A W474X wt wt 
71 f G1924A I642V wt wt 
 
 
 
 
aMicrosatellite genotyping confirmed these cell lines were independent;  
bsamples were homozygous for this mutation. c SSM primary melanoma, no 
chronic sun damage evident; d Acral melanoma, histologically SSM; e  
Mucosal primary melanoma; f Primary Lentigo Maligna Melanoma, with 
histological evidence of chronic sun damage. Nd, not done. g The IVS15-
2A>T is predicted to result in the skipping of exon 16, subsequent frameshift 
for 27aa and a premature truncation at codon 690 in the kinase domain. 
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Table 2. Summary of in-silico analysis of FGFR2 mutations 
 
Novel FGFR2 mutation Predicted effect based on molecular modeling 
 
E160A, H213Y 
 
Negatively impact interaction with HS 
E219K Reduced FGF and heparin mediated receptor dimerization 
G227E, V248D Destabilize the D2 domain 
R251Q Abrogate ligand binding 
G271E Destabilize the D3 domain 
E475K Possible increased kinase activity but less stable kinase domain 
M640I, I642V Local structural perturbations resulting in altered conformation of the activation loop and decreased kinase activity 
A648T Markedly reduced kinase activity due to misalignment of catalytic residues for phosphotransfer reaction 
L770V Impaired phosphorylation of Y769 and reduced recruitment of PLCγ 
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Supplemental Methods- Mutation Analysis 
 
 
PCR .  
The initial mutation screen included the majority of exons in FGFR1 and FGFR2. As 
virtually no mutations had even been reported in the N-terminal regions of the FGFRs, 
exons 1 and 2 were not screened for FGFR3 and exons 1-6 were not screened for FGFR4 
(Summarized in Supplemental Table 2). Notably all exons in which the majority of 
activating mutations had previously been identified in the germline of FGFR1-3 were 
screened across all four genes. PCR primers were M13 tailed and sequences are available 
on request. New PCR primers were designed for FGFR2 for amplification from FFPE 
tissue. 
 
Supplemental Table 2.  
Gene Name Reference Seqence Exons Screened 
FGFR1 NM_023110 Exons 2-18 (ATG in exon 2) 
FGFR2 NM_00141 Exons 2-18 (ATG in exon 2) 
FGFR2 NM_022970  Exon 8 (epithelially spliced exon) 
FGFR3 NM_000142 Exons 3-17 (ATG in exon 1) 
FGFR4 NM_213647 Exons 7-18  (ATG in exon 1) 
   
 
dHPLC. 40 additional cell lines were screened for mutations in exons 6-18 of FGFR2 by 
DHPLC using the Transgenomic WAVE Nucleic Acid Fragment Analysis System. The 
base-pair sequence for each FGFR2 exon was imported in to the WAVEMAKER 
software to identify suitable denaturing conditions (conditions available on request). Prior 
to the samples being loaded, each sample was spiked 50:50 with a CEPH control to 
ensure the detection of both heterozygous and homozygous variants. At the completion of 
DHPLC, chromatograms were printed out and individually analyzed for the presence of a 
potential variation. In those cases where identical DHPLC peak profiles were present in 
many samples, several cases were chosen for sequencing and in all cases a common SNP 
was present and not a mutation. PCR exons were either cleaned up using a PCR 
purification kit (Qiagen) and the BIOROBOT 9600 dual vacuum system (Qiagen) or 
purified after thermocycling using solid phase reversible immobilization (SPRI)-based 
technology (AMPure®; Agencourt Biosciences Corp., Beverly, MA), resulting in the 
removal of unincorporated dNTPs, primers, and salts. PCR products were eluted in 30μl 
distilled H2O 
 
Sequencing:  Both strands of each PCR product were sequenced as follows: Sequencing 
reactions were performed using 3μl (approximately 25ng) of purified PCR product in a 
6μl reaction containing 0.33μl BigDye Terminator v3.1 premix, 3.2 pmol of either M13 
forward (TGTAAAACGACGGCCAGT) or M13 reverse 
(CAGGAAACAGCTATGACC) primer, and 1.03μl 5X BigDye sequencing buffer.  
Cycle-sequencing was performed for 35 cycles following the manufacturers 
recommendations on GeneAmp 9700 PCR machines (Applied Biosystems, Foster City, 
CA). Sequencing reactions were purified using CleanSEQ® (Agencourt Biosciences 
Corp., Beverly, MA) to remove unincorporated dye-terminators, and analyzed on 3730xl 
DNA analyzers (Applied Biosystems, Foster City, CA). 
 
Sequence Analysis and Confirmation.  We aligned and analyzed sequence 
chromatograms using Sequencher Version 4.1 (Gene Codes). All mutations were verified 
in an independent PCR amplification. For the primary tumors, DNA was extracted as 
previously described 39. Due to cccasional PCR failure and limiting DNA quantity, we 
were unable to sequence all 18 exons of FGFR2 for every tumor sample. Overall, about 
85% of the coding region of FGFR2 was sequenced in the panel of primary tumors. PCR 
dropouts were repeated once and samples were included if they had less than 5 exons 
dropout. For three of these tumors, there was sufficient normal tissue from which to 
extract DNA and in all cases the mutation was only present in the tumor, confirming the 
somatic origin of these changes.  
 
 
 
Supplementary Table 1  The following primers were used to introduce mutations 
(sense, 5’ to 3’ with mutagenic changes underlined and silent substitutions in lower case):  
  
E219K CACTGGAGCCTCATTATGAAAAGTGTGGTaCCATCTGA 
G227E GGTCCCATCTGACAAGGAAAAcTATACaTGTGTGGTGGAG 
V248D ACACGTACCACCTGGATGACGTcGAGCGATCGCCTCAC 
R251Q CTGGAcGTTGTcGAGCAATCGCCTCACCGG 
S252W GTTGTGGAGCGcTGGCCTCACCGGC 
G271E CCTCCACAGTcGTCGAAGGAGACGTcGAGTTTG 
C278F TGGTCGGAGGAGACGTcGAGTTTGTCTTCAAGGTTTACAG 
E475K CCAGAGGAtCCAAAATGGAAGTTTCCAAGAGATAAGCTG 
D530N ACAGAGAAAGACCTTTCTAATCTGGTcTCAGAGATGG 
I642V CAGAAAACAATGTcATGAAAGTAGCAGACTTTGGACTCG 
A648T TAGCAGACTTTGGtCTCACCAGAGATATCAACAATATAGAC 
N549K CACAAGAATATCATAAAgCTTCTTGGAGCCTGCACAC 
 
 
  
